Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Drug Discovery World
NOVEMBER 7, 2023
Watch this on-demand webinar to learn: How Spectral Shift technology lets you take measurements in-solution and immobilisation free What the data from a Spectral Shift experiment characterising protein degraders looks like How to save time and sample by reducing the need for complex assay development when working with binary and ternary interactions (..)
Let's personalize your content